| Methods |
Randomised clinical trial |
| Participants |
Country: Hungary.
Number randomised: 36.
Post‐randomisation dropouts: not stated.
Revised sample size: 36.
Average age: 46 years.
Females: 9 (25%).
Inclusion criteria: ALD
Exclusion criteria: other causes of liver disease |
| Interventions |
Participants were randomly assigned to two groups.
Group 1 (n = 17): silymarin 140 mg thrice daily.
Group 2 (n = 19): placebo.
Duration: 6 months treatment |
| Outcomes |
adverse events. |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Quote: "Random code".
Comment: Further details were not available. |
| Allocation concealment (selection bias) |
Unclear risk |
Comment: this information was not available. |
| Blinding of participants and personnel (performance bias)
All outcomes |
Unclear risk |
Quote: "Double‐blind".
Comment: Further details were not available. |
| Blinding of outcome assessment (detection bias)
All outcomes |
Unclear risk |
Quote: "Double‐blind".
Comment: Further details were not available. |
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
Comment: this information was not available. |
| Selective reporting (reporting bias) |
High risk |
Comment: mortality was not reported. |
| For‐profit bias |
Unclear risk |
Comment: this information was not available. |
| Other bias |
Low risk |
Comment: there was no other bias. |
